Conversion of murine antibodies to human antibodies and their optimization for ovarian cancer therapy targeted to the folate receptor

Cancer Immunology, Immunotherapy

Volumn 58, Issue 4, 2009, Pages 531-546

  Figini, Mariangela ^a   Martin, Franck ^b   Ferri, Renata ^a   Luison, Elena ^a   Ripamonti, Elena ^a   Zacchetti, Alberto ^a   Mortarino, Mimosa ^a   Di Cioccio, Vito ^b   Maurizi, Giovanni ^b   Allegretti, Marcello ^b   Canevari, Silvana ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b Chemistry Section   (Italy)

Author keywords

Antibody fragment; Chemical dimerization; Folate receptor; Ovarian cancer; Phage display

Indexed keywords

COMPLEMENT COMPONENT C4; FOLATE RECEPTOR; FOLATE RECEPTOR ANITIBODY 1; FOLATE RECEPTOR ANITIBODY 2; FOLATE RECEPTOR ANITIBODY 3; FOLATE RECEPTOR ANITIBODY 4; FOLATE RECEPTOR ANITIBODY 5.3; IMMUNOGLOBULIN F(AB) FRAGMENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY AFFINITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DIMERIZATION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG RECEPTOR BINDING; DRUG TARGETING; FEMALE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; OVARY CARCINOMA; PHAGE DISPLAY; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES; ANTIBODY SPECIFICITY; CARRIER PROTEINS; DIMERIZATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; MICE; OVARIAN NEOPLASMS; PEPTIDE LIBRARY; RECEPTORS, CELL SURFACE; RECOMBINANT FUSION PROTEINS;

EID: 59449084792     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-008-0575-5     Document Type: Article

References (38)

1. Committee on cancer research (UKCCCR), United Kingdom (1998) Guidelines for the welfare of animals in experimental neoplasia, 2nd edn. Br J Cancer 77: 1-10
2. M Adamczyk JC Gebler J Wu Z Yu 2002 Complete sequencing of anti-vancomycin Fab fragment by liquid chromatography-electrospray ion trap mass spectrometry with a combination of database searching and manual interpretation of the MS/MS spectra J Immunol Methods 260 235 249
3. S Alberti S Miotti M Fornaro L Mantovani S Walter S Canevari S Ménard MI Colnaghi 1990 The Ca-MOv18 molecule, a cell-surface marker of human ovarian carcinomas, is anchored to the cell membrane by phosphatidylinositol Biochem Biophys Res Commun 171 1051 1055
4. SS Brack M Silacci M Birchler D Neri 2006 Tumor-targeting properties of novel antibodies specific to the large isoform of tenascin-C Clin Cancer Res 12 3200 3208
5. S Canevari SM Pupa S Menard 1996 1975-1995 revised anti-cancer serological response: biological significance and clinical implications Ann Oncol 7 227 232
6. S Canevari G Stoter F Arienti G Bolis MI Colnaghi E Di Re AMM Eggermont SH Goey JW Gratama CHJ Lamers MA Nooy G Parmiani F Raspagliesi F Ravagnani G Scarfone JB Trimbos SO Warnaar RLH Bolhuis 1995 Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T-lymphocytes retargeted by a bispecific monoclonal antibody J Natl Cancer Inst 87 1463 1469
7. PJ Carter 2006 Potent antibody therapeutics by design Nat Rev Immunol 6 343 357
8. P Casalini E Luison S nard MI Colnaghi G Paganelli S Canevari 1997 Tumor pretargeting: role of avidin/streptavidin on monoclonal antibody internalization J Nucl Med 38 1378 1381
9. P Casalini D Mezzanzanica S Canevari G Della Torre S Miotti MI Colnaghi S Matzku 1991 Use of combination of monoclonal antibodies directed against three distinct epitopes of a tumor-associated antigen: analysis of cell binding and internalization Int J Cancer 48 284 290
10. JL Casey DJ King LC Chaplin AM Haines RB Pedley A Mountain GT Yarranton RH Begent 1996 Preparation, characterisation and tumour targeting of cross-linked divalent and trivalent anti-tumour Fab' fragments Br J Cancer 74 1397 1405
11. A Coliva A Zacchetti E Luison A Tomassetti I Bongarzone E Seregni E Bombardieri F Martin A Giussani M Figini S Canevari 2005 90Y labeling of monoclonal antibody MOv18 and preclinical validation for radioimmunotherapy of human ovarian carcinomas Cancer Immunol Immunother 54 1200 1213
12. LR Coney D Mezzanzanica D Sanborn P Casalini MI Colnaghi VR Zurawski Jr 1994 Chimeric murine-human antibodies directed against folate binding receptor are efficient mediators of ovarian carcinoma cell killing Cancer Res 54 2448 2455
13. LR Coney A Tomassetti L Carayannopoulos V Frasca BA Kamen MI Colnaghi VR Zurawski Jr 1991 Cloning of a tumor-associated antigen: MOv18 and MOv19 antibodies recognize a folate-binding protein Cancer Res 51 6125 6132
14. JA Coronella-Wood EM Hersh 2003 Naturally occurring B-cell responses to breast cancer Cancer Immunol Immunother 52 715 738
15. F Crippa G Bolis E Seregni N Gavoni E Bombardieri G Scarfone C Ferrari GL Buraggi 1995 Single dose intraperitoneal radioimmunotherapy with the murine monoclonal antibody 131I-MOv18: clinical results in patients with minimal residual disease of ovarian cancer Eur J Cancer 31A 686 690
16. J de Kruif AR van der Vuurst de Vries L Cilenti E Boel W van Ewijk T Logtenberg 1996 New perspectives on recombinant human antibodies Immunol Today 17 453 455
17. M Figini R Ferri D Mezzanzanica M Bagnoli E Luison S Miotti S Canevari 2003 Reversion of transformed phenotype in ovarian cancer cells by intracellular expression of anti-folate receptor antibodies Gene Ther 10 1018 1025
18. M Figini JD Marks G Winter AD Griffiths 1994 In vitro assembly of repertoires of antibody chains on the surface of phage by renaturation J Mol Biol 239 68 78
19. M Figini L Obici D Mezzanzanica AD Griffiths MI Colnaghi G Winter S Canevari 1998 Panning phage antibody libraries on cells: isolation of human Fab fragments against ovarian carcinoma using guided selection Cancer Res 58 991 996
20. A Groulet M Dorvillius A Pelegrin J Barbet D Baty 2002 Pharmacokinetic and tumor-seeking properties of recombinant and nonrecombinant anti-carcinoembryonic antigen antibody fragments Int J Cancer 100 367 374
21. M Jain G Venkatraman SK Batra 2007 Optimization of radioimmunotherapy of solid tumors: biological impediments and their modulation Clin Cancer Res 13 1374 1382
22. KL Knutson CJ Krco CL Erskine K Goodman LE Kelemen PJ Wettstein PS Low LC Hartmann KR Kalli 2006 T-cell immunity to the folate receptor alpha is prevalent in women with breast or ovarian cancer J Clin Oncol 24 4254 4261
23. B Liu F Conrad A Roth DC Drummond JP Simko JD Marks 2007 Recombinant full-length human IgG1s targeting hormone-refractory prostate cancer J Mol Med 85 1113 1123
24. L Loo MK Robinson GP Adams 2008 Antibody engineering principles and applications Cancer J 14 3 149 153
25. P Macor D Mezzanzanica C Cossetti P Alberti M Figini S Canevari F Tedesco 2006 Complement activated by chimeric anti-folate receptor antibodies is an efficient effector system to control ovarian carcinoma Cancer Res 66 3876 3883
26. JD Marks WH Ouwehand JM Bye R Finnern BD Gorick D Voak S Thorpe NC Hughes-Jones G Winter 1993 Human antibody fragments specific for human blood group antigens from a phage display library Biotechnology 11 1145 1149
27. S Mayor KG Rothberg FR Maxfield 1994 Sequestration of GPI-anchored proteins in caveolae triggered by cross-linking Science 264 1948 1951
28. RF Meredith DJ Buchsbaum RD Alvarez AF LoBuglio 2007 Brief overview of preclinical and clinical studies in the development of intraperitoneal radioimmunotherapy for ovarian cancer Clin Cancer Res 13 5643s 5645s
29. S Miotti S Canevari S Ménard D Mezzanzanica G Porro SM Pupa M Regazzoni E Tagliabue MI Colnaghi 1987 Characterization of human ovarian carcinoma-associated antigens defined by novel monoclonal antibodies with tumor-restricted specificity Int J Cancer 39 297 303
30. S Miotti DR Negri O Valota M Calabrese RL Bolhuis JW Gratama MI Colnaghi S Canevari 1999 Level of anti-mouse antibody response induced by bispecific monoclonal antibody OC/TR in ovarian carcinoma patients is associated with longer survival Int J Cancer 84 62 68
31. GR Mirick BM Bradt SJ Denardo GL Denardo 2004 A review of human anti-globulin antibody (HAGA, HAMA, HACA, HAHA) responses to monoclonal antibodies. Not four letter words Q J Nucl Med Mol Imaging 48 251 257
32. F Ottone S Miotti C Bottini M Bagnoli P Perego MI Colnaghi S Ménard 1997 Relationship between folate binding protein expression and cisplatin sensitivity in ovarian carcinoma cell lines Br J Cancer 76 77 82
33. LG Presta 2006 Engineering of therapeutic antibodies to minimize immunogenicity and optimize function Adv Drug Deliv Rev 58 640 656
34. JM Reichert VE Valge-Archer 2007 Development trends for monoclonal antibody cancer therapeutics Nat Rev Drug Discov 6 349 356
35. ML Rodrigues B Snedecor C Chen WL Wong S Garg GS Blank D Maneval P Carter 1993 Engineering Fab' fragments for efficient F(ab)2 formation in Escherichia coli and for improved in vivo stability J Immunol 151 6954 6961
36. MW Saif A Zalonis K Syrigos 2007 The clinical significance of autoantibodies in gastrointestinal malignancies: an overview Expert Opin Biol Ther 7 493 507
37. MD Salazar M Ratnam 2007 The folate receptor: what does it promise in tissue-targeted therapeutics? Cancer Metastasis Rev 26 141 152
38. G Toffoli C Cernigoi A Russo A Gallo M Bagnoli M Boiocchi 1997 Overexpression of folate binding protein in ovarian cancers Int J Cancer 74 193 198